Endo Health Solutions Inc: (NASD: ENDP)
$33.41
-0.33 (-0.98%)
Volume 1,697,365
May 15 03:41 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 33.27 - 33.86 |
| 52wk Low - High | 25.01 - 38.32 |
| Previous Close | 33.74 |
| Avg. Volume | 2,899,641 |
| Industry | MED-DRUGS |
| Market Cap | 3.74 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.74 |
| PE (Forward) | 7.80 |
| Current Year Est. | 4.32 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
86 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 7.80 |
| PEG Ratio | 1.12 |
| Current Year Est. | 4.32 |
| Current Quarter Estimate | 1.17 |
| Most Accurate Estimate | 1.17 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | 5.26 |
| Expected Earnings Growth | 6.95% |
Company Description
Endo Pharmaceuticals Holdings Inc., through its wholly owned subsidiaries, Endo Pharmaceuticals Inc. and Endo Inc., is engaged in the research, development, sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 1.17 | 1.08 | 4.32 | 3.65 |
| Number of Estimates | 13 | 12 | 15 | 14 |
| Low Estimate | 1.11 | 0.96 | 4.00 | 2.81 |
| High Estimate | 1.28 | 1.21 | 4.70 | NA |
| Year Ago EPS | 1.27 | 1.28 | 5.02 | 4.32 |
| EPS Growth | -7.51% | -15.56% | -13.85% | -15.63% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ENDO PHARMACEUT | ENDP | 33.74 | |
|
| CATALYST PHARMA | CPRX | 0.90 | |
|
| JAZZ PHARMACEUT | JAZZ | 59.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.29 | |
|
| SANTARUS INC | SNTS | 21.02 | |
|
| USANA HLTH SCI | USNA | 60.62 | |
|
| BIOCRYST PHARMA | BCRX | 1.81 | |
|
| CELL THERAPEUT | CTIC | 1.19 | |
|
| CUBIST PHARM | CBST | 48.77 | |
|
| ELAN CP PLC ADR | ELN | 11.45 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Setback for Endo Health on Opana ER
May 13, 2013
Earnings Beat at Endo Health, Sales Slip
May 08, 2013
Company News for May 8, 2013
May 08, 2013
Back to Neutral on Endo Health
Mar 06, 2013
Actavis Files ANDA for Endo Product
Mar 05, 2013
Earnings Beat at Endo Health
Mar 04, 2013
Stock Market News for February 19, 2013
Feb 19, 2013
Endo Inks Deal with Indian Company
Jan 29, 2013
Financials
| EPS TTM | 5.26 |
| Sales | 3,027 |
| Net Income | -638 |
| Price/Earnings | 6.41 |
| Price/Book | 3.20 |
| Price/Cash Flow | 4.17 |
| Price/Sales | 1.23 |
News
AFFY, GALE, and AVEO added to BioStock Watch List at GSR - Accesswire-Tnw
May 14, 2013
Market Maker Surveillance Report. BAC, RAD, FITB, S, ENDP, FINMY, Bearishly Biased Price Friction For Monday, May 13th 2013 - M2
May 14, 2013
Reveal Insider Trading in J.C. Penney, Gilead Sciences, Chesapeake Energy, Annaly Capital Management, Endo Health Solutions, and Zynga - Pr Newswire
May 14, 2013
Analyst Moves: ENDP, PRU, AZO - Marketnewsvideo.Com
May 13, 2013
Benzinga`s Top Pre-Market Losers - Benzinga
May 13, 2013
Endo Pharmaceuticals Shares Sinking Lower, Down 2.7% - Financial News Network Online - Market Movers
May 13, 2013
FDA Not Buying Endo Health???s Painkiller Ploy - YCharts
May 13, 2013
Stocks Weaken In Late Trade; Qihoo, YY Slide - Investors Business Daily
May 13, 2013
Broker Recommendations
| Current ABR | 2.79 |
| ABR (Last Week) | 2.58 |
| # of recs in ABR | 19 |
| Average Target Price | 34.71 |
| Industry Rank by ABR | 86 out of 265 |
| Rank in Industry | 17 out of 91 |
